Search Within

Sydney X Lu

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (58)
  2. Journal Article (39)
  3. Research Letter (2)
  4. Review (1)
Groups
  1. Department of Medicine (100)
  2. Hematologic Malignancies, Division of (100)
  3. Center for Hematologic Malignancies (99)
  4. GSK Faculty (71)
  5. Executive Committee, Center for Hematologic Malignancies (70)
  6. Sloan Kettering Institute Postdocs (59)

More Groups

People
  1. Marcel Van Den Brink (45)
  2. David Suh (33)
  3. Alexander Lesokhin (32)
  4. Malin Hultcrantz (32)
  5. Neha Korde (31)
  6. Odette Smith (31)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (11)
  4. 2021 (12)
  5. 2020 (11)
  6. 2019 (11)

More Years

Publications
  1. Blood (43)
  2. Biology of Blood and Marrow Transplantation (12)
  3. Clinical Lymphoma, Myeloma and Leukemia (4)
  4. Journal of Clinical Oncology (4)
  5. Journal of Immunology (3)
  6. Bone Marrow Transplantation (2)

More Publications

Publishers
  1. American Society of Hematology (43)
  2. Elsevier Inc. (17)
  3. Nature Publishing Group (10)
  4. American Society of Clinical Oncology (4)
  5. The American Association of Immunologists, Inc (3)
  6. American Association for Cancer Research (2)

More Publishers

Results (100)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Research Letter

    Bewersdorf, J. P.; Stahl, M.; Taylor, J.; Mi, X.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Lu, S. X.; Bourcier, J.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms
    Meeting Abstract

    Diamond, B.; Ziccheddu, B.; Boyle, E. M.; Maclachlan, K.; Taylor, J.; Watts, J. M.; Lu, S. X.; Coffey, D. G.; Bolli, N.; Papaemmanuil, E.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
    Meeting Abstract

    Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes
    Meeting Abstract

    Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Attenuation of graft-versus-host-disease via genetic or pharmacologic inhibition of the RNA splicing factor RBM39
    Meeting Abstract

    Bourcier, J.; Hogg, S. J.; Erickson, C.; Singer, M. E.; Tittley, S.; Ito, T.; Egorova, A.; Kuttiyara, J.; Hanash, A. M.; Abdel-Wahab, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save